According to a first embodiment, there is provided a sustained-release preparation comprising a water-insoluble or slightly water-soluble polyvalent metal salt of a water-soluble physiologically active substance which is not an endothelin antagonist, and a biodegradable polymer. The sustained-release preparation of the first embodiment is highly efficient in incorporating the water-soluble physiologically active substance and suppresses the initial burst of the water-soluble physiologically active substance. The sustained-release preparation of the present invention is capable of releasing the water-soluble physiologically active substance while retaining its bioactivity after administration in vivo. Furthermore, the water-soluble physiologically active substance in the sustained-release preparation is kept stable for a long period of time, with little loss of bioactivity.
According to a second embodiment, there is provided a sustained-release preparation comprising an anti-endothelin substance and a biodegradable polymer. The sustained-release preparation of the present invention sustainedly releases an anti-endothelin substance, serving well in the treatment of endothelin-associated diseases.
根据第一个实施方案,提供了一种缓释制剂,该制剂包含一种不溶于
水或微溶于
水的
水溶性生理活性物质的多价
金属盐,该生理活性物质不是内皮素拮抗剂,还包含一种可
生物降解的聚合物。第一实施方案中的缓释制剂能高效地掺入
水溶性生理活性物质,并抑制
水溶性生理活性物质的初始迸发。本发明的缓释制剂能够释放
水溶性生理活性物质,同时在体内给药后保持其
生物活性。此外,本发明的缓释制剂中的
水溶性生理活性物质可保持长期稳定,
生物活性损失小。 根据第二个实施方案,本发明提供了一种由抗内皮素物质和
生物可降解聚合物组成的缓释制剂。本发明的缓释制剂可持续释放抗内皮素物质,在治疗内皮素相关疾病中发挥良好作用。